Your browser doesn't support javascript.
loading
Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration.
Tracy, Tara E; Madero-Pérez, Jesus; Swaney, Danielle L; Chang, Timothy S; Moritz, Michelle; Konrad, Csaba; Ward, Michael E; Stevenson, Erica; Hüttenhain, Ruth; Kauwe, Grant; Mercedes, Maria; Sweetland-Martin, Lauren; Chen, Xu; Mok, Sue-Ann; Wong, Man Ying; Telpoukhovskaia, Maria; Min, Sang-Won; Wang, Chao; Sohn, Peter Dongmin; Martin, Jordie; Zhou, Yungui; Luo, Wenjie; Trojanowski, John Q; Lee, Virginia M Y; Gong, Shiaoching; Manfredi, Giovanni; Coppola, Giovanni; Krogan, Nevan J; Geschwind, Daniel H; Gan, Li.
Afiliação
  • Tracy TE; Gladstone Institutes, San Francisco, CA 94158, USA; Buck Institute for Research on Aging, Novato, CA 94945, USA. Electronic address: ttracy@buckinstitute.org.
  • Madero-Pérez J; Helen and Robert Appel Alzheimer Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10021, USA. Electronic address: jem4002@med.cornell.edu.
  • Swaney DL; Gladstone Institutes, San Francisco, CA 94158, USA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, USA; Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address: danielle
  • Chang TS; Department of Neurology, Movement Disorders Program and Program in Neurogenetics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
  • Moritz M; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, USA.
  • Konrad C; Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10065, USA.
  • Ward ME; Gladstone Institutes, San Francisco, CA 94158, USA.
  • Stevenson E; Gladstone Institutes, San Francisco, CA 94158, USA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, USA; Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA 94158, USA.
  • Hüttenhain R; Gladstone Institutes, San Francisco, CA 94158, USA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, USA; Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA 94158, USA.
  • Kauwe G; Buck Institute for Research on Aging, Novato, CA 94945, USA.
  • Mercedes M; Helen and Robert Appel Alzheimer Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10021, USA.
  • Sweetland-Martin L; Helen and Robert Appel Alzheimer Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10021, USA.
  • Chen X; Gladstone Institutes, San Francisco, CA 94158, USA.
  • Mok SA; Department of Biochemistry, University of Alberta, Edmonton, AB T6G 2R3, Canada.
  • Wong MY; Helen and Robert Appel Alzheimer Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10021, USA.
  • Telpoukhovskaia M; Gladstone Institutes, San Francisco, CA 94158, USA.
  • Min SW; Gladstone Institutes, San Francisco, CA 94158, USA.
  • Wang C; Gladstone Institutes, San Francisco, CA 94158, USA.
  • Sohn PD; Gladstone Institutes, San Francisco, CA 94158, USA.
  • Martin J; Gladstone Institutes, San Francisco, CA 94158, USA.
  • Zhou Y; Gladstone Institutes, San Francisco, CA 94158, USA.
  • Luo W; Helen and Robert Appel Alzheimer Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10021, USA.
  • Trojanowski JQ; Center for Neurodegenerative Disease Research, School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Lee VMY; Center for Neurodegenerative Disease Research, School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Gong S; Helen and Robert Appel Alzheimer Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10021, USA.
  • Manfredi G; Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10065, USA.
  • Coppola G; Department of Neurology, Movement Disorders Program and Program in Neurogenetics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA; Department of Psychiatry, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA 90095, USA
  • Krogan NJ; Gladstone Institutes, San Francisco, CA 94158, USA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, USA; Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA 94158, USA.
  • Geschwind DH; Department of Neurology, Movement Disorders Program and Program in Neurogenetics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA; Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; I
  • Gan L; Helen and Robert Appel Alzheimer Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10021, USA. Electronic address: lig2033@med.cornell.edu.
Cell ; 185(4): 712-728.e14, 2022 02 17.
Article em En | MEDLINE | ID: mdl-35063084
ABSTRACT
Tau (MAPT) drives neuronal dysfunction in Alzheimer disease (AD) and other tauopathies. To dissect the underlying mechanisms, we combined an engineered ascorbic acid peroxidase (APEX) approach with quantitative affinity purification mass spectrometry (AP-MS) followed by proximity ligation assay (PLA) to characterize Tau interactomes modified by neuronal activity and mutations that cause frontotemporal dementia (FTD) in human induced pluripotent stem cell (iPSC)-derived neurons. We established interactions of Tau with presynaptic vesicle proteins during activity-dependent Tau secretion and mapped the Tau-binding sites to the cytosolic domains of integral synaptic vesicle proteins. We showed that FTD mutations impair bioenergetics and markedly diminished Tau's interaction with mitochondria proteins, which were downregulated in AD brains of multiple cohorts and correlated with disease severity. These multimodal and dynamic Tau interactomes with exquisite spatial resolution shed light on Tau's role in neuronal function and disease and highlight potential therapeutic targets to block Tau-mediated pathogenesis.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sinapses / Proteínas tau / Mapas de Interação de Proteínas / Mitocôndrias / Degeneração Neural Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sinapses / Proteínas tau / Mapas de Interação de Proteínas / Mitocôndrias / Degeneração Neural Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article